NewAmsterdam is moving from a late-stage cardiovascular development story toward a broader cardiometabolic and neurodegenerative platform; its European obicetrapib commercialization effort has also advanced, while several cardiovascular Phase 3 programs remain active.
The Alzheimer’s program has officially moved into clinical testing. The first participant has been dosed in SPINOZA, a randomized Phase 2b study testing obicetrapib in people with biomarker evidence of preclinical Alzheimer’s disease but no noticeable symptoms.
| Filing metric | SPINOZA design |
|---|---|
| Planned enrollment | Approximately 400 participants (About the Phase 2b SPINOZA Trial) |
| Treatment period | 52 weeks double-blind (About the Phase 2b SPINOZA Trial) |
| Dose | Obicetrapib 10 mg or placebo, randomized 1:1 (About the Phase 2b SPINOZA Trial) |
| Primary endpoint | Change in plasma p-tau217 at Week 52 (About the Phase 2b SPINOZA Trial) |
| Optional extension | At least 26 weeks open-label (About the Phase 2b SPINOZA Trial) |
This is a development milestone, not an efficacy readout. The trial will measure whether obicetrapib changes Alzheimer’s-related blood biomarkers, led by p-tau217, alongside cognitive measures; no SPINOZA safety or efficacy results are available yet. 〔0〕
The scientific rationale is promising but still indirect. NewAmsterdam is carrying forward a prespecified BROADWAY biomarker analysis in which p-tau217 changes were statistically lower versus placebo, including among ApoE4 carriers, but that analysis came from a cardiovascular trial subset that was not controlled for baseline differences and did not include a safety analysis in the Alzheimer’s population. 〔1〕
The surprise is limited because trial initiation was already part of the 2026 plan. What is new is execution—the first patient is dosed and the genotype-stratified design is underway—not a change in strategy or proof that obicetrapib affects Alzheimer’s disease. The company still has to show that a biomarker effect translates into meaningful disease modification.
Bottom line: SPINOZA broadens obicetrapib’s opportunity and confirms NewAmsterdam is executing on a previously signaled Alzheimer’s expansion. It matters strategically, but it does not yet change the evidence base for the drug in neurodegenerative disease.
Read the original 8-K on SEC EDGAR ↗